GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (NAS:AGEN) » Definitions » Book Value per Share

Agenus (Agenus) Book Value per Share : $-8.13 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Agenus Book Value per Share?

Agenus's book value per share for the quarter that ended in Dec. 2023 was $-8.13.

During the past 3 years, the average Book Value Per Share Growth Rate was 26.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Agenus was 50.30% per year. The lowest was -54.20% per year. And the median was 5.00% per year.

Agenus's current price is $8.30. Its book value per share for the quarter that ended in Dec. 2023 was $-8.13. Hence, today's PB Ratio of Agenus is .

During the past 13 years, the highest P/B Ratio of Agenus was 240.87. The lowest was 2.46. And the median was 10.53.


Agenus Book Value per Share Historical Data

The historical data trend for Agenus's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Book Value per Share Chart

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.70 -20.77 2.68 -4.01 -8.13

Agenus Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.01 -3.43 -5.07 -6.77 -8.13

Competitive Comparison of Agenus's Book Value per Share

For the Biotechnology subindustry, Agenus's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's PB Ratio distribution charts can be found below:

* The bar in red indicates where Agenus's PB Ratio falls into.



Agenus Book Value per Share Calculation

Agenus's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-160.3-0.0)/19.7
=-8.13

Agenus's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-160.3-0.0)/19.7
=-8.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Agenus  (NAS:AGEN) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Agenus Book Value per Share Related Terms

Thank you for viewing the detailed overview of Agenus's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus (Agenus) Business Description

Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Executives
Ulf Wiinberg director
Steven J O'day officer: Chief Medical Officer 2344 BANYAN DRIVE, LOS ANGELES CA 90049
Garo H Armen officer: Chairman & CEO 3 FORBES ROAD, LEXINGTON MA 02421
Christine M Klaskin officer: VP Finance 3 FORBES ROAD, LEXINGTON MA 02421
Adam Krauss officer: Chief Legal Officer 139 GRANIT STREET, MEDFIELD MA 02052
Susan B Hirsch director 280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Paul N Clark director 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Incyte Corp 10 percent owner 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Alex Duncan officer: Chief Technology Officer 3 FORBES ROAC, LEXINGTON MA 02421
Christian Cortis officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Evan Kearns officer: V.P. and General Counsel AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
Jennifer Buell officer: Chief Operating Officer 3 FORBES ROAD, LEXINGTON MA 02421
Allison M Jeynes-ellis director FLAT 52, WILLIAM HUNT MANSIONS, LONDON X0 SW13 8HT
Wadih Jordan director ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010